Skip to main content

Advertisement

Table 5 Overview of Adverse Events

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

Event Grade Cilengitide + Gemcitabine n = 44 Gemcitabine n = 42
   No. Pts (%) No. Pts (%)
AE All 923 100% 755 100%
  Grade 1/2 812 27% 617 17%
  Grade 3/4 111 73% 138 83%
SAE All 50 55% 64 71%
  1. Adverse events with onset during the treatment phase.
  2. Abbreviations: Pts, patients; AE, adverse event; SAE, serious adverse event.